13例涎腺腺癌的临床分析  

Clinical Analysis for Therapy and Prognosis of Adenocarcinoma Salivary Glands: A Report of 13 Cases

作　　者：邓润智[1] 唐恩溢[1] 黄晓峰[2] 王志勇[1] 陈菲[2] 

机构地区：[1]南京市口腔医院颌面外科,南京市210008 [2]南京市口腔医院病理科,南京市210008

出　　处：《中国肿瘤临床》2006年第9期518-520,共3页Chinese Journal of Clinical Oncology

摘　　要：目的:了解涎腺腺癌发病情况、构成特点,并探讨13例涎腺腺癌的治疗方式和治疗效果,指导临床实践。方法:按照WHO涎腺肿瘤组织学分类标准,对13例经病理确诊的涎腺腺癌部位分布、发病年龄、性别进行回顾性分析,并对其术后生存情况进行长期跟踪随访。结果:腮腺是最主要发病部位。男性患者(61.5%)稍多于女性(38.5%)。涎腺腺癌患者平均发病年龄49.6岁,13例涎腺腺癌患者中位生存时间为8.5年,3年生存率为83.3%,5年生存率为66.7%。结论:涎腺腺癌发病男性占优势,以腮腺最好发,手术治疗为主,首次手术彻底为治疗关键,治疗计划需个性化,患者死亡主要发生于术后6年之内,过后生存时间显著延长。Objective： To investigate the clinical features, the operative type and therapeutic-efficacy of adenoeareinoma salivary glands. Methods： Thirteen cases of salivary glands adenocarcinoma were reviewed and pathologic diagnosis was based on the WHO Classification. The clinical features were retrospectively analyzed and followed-up for prognosis. Results： Parotid gland was the most common location of salivary adenocarcinoma. In the 13 cases, the average age of onset was 49.6, with a male preponderance. The median survival time, 3-year and 5-year survival rate was 8.5years, 83.3%, and 66.7%, respectively. Conclusions： The male patients predominate in the incidence of adenocarcinoma salivary glands, with parotid as the predilection site, surgical operation as the main treatment, complete initial-operation as the key of the treatment. Individualization is needed in the regimens. The mortality occurs mainly within 6 years after operation, after which the survival time significantly prolongs.

关 键 词：涎腺 腺癌 预后 

分 类 号：R739.8[医药卫生—肿瘤]